JURA.Bio is a pioneering biotechnology company that combines AI and synthetic biology to develop next-generation genomic medicines and immune-based therapies. The company focuses on the discovery and development of novel TCR (T-cell receptor) therapies targeting the TCR-epitope-HLA synapse, a critical biological target for personalized medicine and immunotherapy.
Key features and capabilities include:
-
End-to-End Discovery Platform: JURA.Bio’s platform integrates generative machine learning and synthetic biology to design, build, and test new therapeutic molecules at scale.
-
Large-Scale TCR Library: The company has developed a library of over 100 billion human TCR candidates, enabling the discovery of antigen-specific TCRs for various diseases, including prostate cancer and other neoantigen targets.
-
Predictive Modeling: JURA.Bio uses advanced machine learning models to predict complex molecular interactions, accelerating the development of safe and effective therapies.
-
Applications in Oncology and Autoimmunity: The platform is designed to address challenging targets in cancer and autoimmune diseases, with a focus on developing therapies that are both effective and safe.
JURA.Bio’s innovative approach is ideal for applications in personalized medicine, cancer immunotherapy, and the development of novel genomic medicines.